CAS NO: | 1421373-98-9 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Name: AZ5104 (Osimertinib metabolite) CAS#: 1421373-98-9 Chemical Formula: C27H31N7O2 Exact Mass: 485.25392 Molecular Weight: 485.58 Elemental Analysis: C, 66.78; H, 6.43; N, 20.19; O, 6.59 | |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Technical Information | Synonym: Demethylated AZ9291; active metabolite of AZD9291 (Osimertinib); AZ5104; AZ-5104; Chemical Name: N-(5-((4-(1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide InChi Key: IQNVEOMHJHBNHC-UHFFFAOYSA-NInChi Code: InChI=1S/C27H31N7O2/c1-6-26(35)30-22-15-23(25(36-5)16-24(22)34(4)14-13-33(2)3)32-27-28-12-11-21(31-27)19-17-29-20-10-8-7-9-18(19)20/h6-12,15-17,29H,1,13-14H2,2-5H3,(H,30,35)(H,28,31,32) SMILES Code: C=CC(NC1=CC(NC2=NC=CC(C3=CNC4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O. |
In Vitro | In vitro activity: AZ5104 shows great potency against ex19del (2 nM in PC-9), T790M (2 nM in H1975), and wild-type EGFR (33 nM in LOVO) cell lines. AZ5104 causes inhibition of cell viability with IC50 of 3.3 nM, 2.6 nM, 80 nM, and 53 nM for H1975 (T790M/L858R), PC-9 (ex19del), Calu 3 (WT), and NCI-H2073 (WT), respectively. Kinase Assay: Kinase assays are performed using peptide or protein substrates in a filter-binding radioactive ATP transferase assay for protein kinases, or lipid substrates and HTRF assay for lipid kinase. Cell Assay: Cells were treated for 2 h with a dose-response of each drug (AZ-5104). Wild-type cells were stimulated for 10 minutes with 25 ng/mL of EGF before lysis. Level of EGFR phosphorylation was quantified in cell extracts using ELISA |
---|---|
In Vivo | In both C/L858R and C/L+T mice, AZ5104 (5 mg/kg/d, p.o.) induces significant and sustained tumor regression. |
Animal model | Mice bearing C/L858R and C/L+T tumors |
Formulation & Dosage | Dissolved in 1% Polysorbate 80; 5 mg/kg; Oral gavage |
References | Cancer Discov. 2014 Sep;4(9):1046-61. |